| Schedule of Segment Reporting Information |
The
following table presents disaggregated financial information with respect to the Company’s Clinical Stage Biotechnology segment
for the three months ended March 31, 2026 and 2025, respectively:
Schedule
of Segment Reporting Information
| | |
2026 | | |
2025 | |
| | |
For the Three Months Ended | |
| | |
March 31, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Grant Revenue | |
$ | - | | |
$ | 278,628 | |
| Operating Expenses: | |
| | | |
| | |
| Research and development | |
| | | |
| | |
| Clinical trial and research expenses | |
| 189,138 | | |
| 250,496 | |
| Insurance | |
| 39,663 | | |
| 47,989 | |
| Payroll and taxes | |
| 78,017 | | |
| 82,179 | |
| Stock based compensation | |
| 13,342 | | |
| 13,894 | |
| Rent and utilities | |
| 9,064 | | |
| 8,146 | |
| Travel and entertainment | |
| 4,110 | | |
| - | |
| Total research and development | |
| 333,334 | | |
| 402,704 | |
| General and administrative | |
| | | |
| | |
| Depreciation | |
| 466 | | |
| 466 | |
| Directors fees | |
| 77,500 | | |
| 77,500 | |
| Donations | |
| - | | |
| 50,000 | |
| Insurance | |
| 35,305 | | |
| 26,760 | |
| Legal fees | |
| 143,351 | | |
| 121,022 | |
| Other general and administrative expenses | |
| 27,631 | | |
| 16,872 | |
| Payroll and taxes | |
| 221,673 | | |
| 216,713 | |
| Professional fees | |
| 109,955 | | |
| 158,627 | |
| Rent and utilities | |
| 5,294 | | |
| 4,651 | |
| Stock based compensation | |
| 292,709 | | |
| 301,206 | |
| Travel and entertainment | |
| 685 | | |
| - | |
| Foreign currency transaction losses | |
| - | | |
| 48 | |
| Total general and administrative | |
| 914,569 | | |
| 973,865 | |
| Total Operating Loss | |
| (1,247,903 | ) | |
| (1,097,941 | ) |
| Other Expense: | |
| | | |
| | |
| Interest expense | |
| (53,046 | ) | |
| (63,661 | ) |
| Net Loss | |
$ | (1,300,949 | ) | |
$ | (1,161,602 | ) |
|